RxDoctor Payments Data

Melissa Wynn, MD

Infectious Disease · Savannah, GANPI 1215934898

Payments from drug & device makers

$9,513in general payments, 2019–2025

Across 529 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • Merck$1K
  • AbbVie$981
  • Astellas Pharma US Inc$903
  • Insmed, Inc.$772
  • plus $3K from 16 others

What the payments were for

  • Speaking & faculty fees$140%
  • Food & beverage$8,59090%
  • Education$90910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,513 in reported general payments places this provider in the 75th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$354,863
Medicare patients
589
Services billed
4,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala172$685,165
GenvoyaElviteg/Cob/Emtri/Tenof Alafen54$210,330
TivicayDolutegravir Sodium47$148,885
Daptomycin75$145,562
OdefseyEmtricitab/Rilpiviri/Tenof Ala40$137,336
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf25$126,096
IsentressRaltegravir Potassium46$93,291
PrezcobixDarunavir/Cobicistat34$80,917
CresembaIsavuconazonium Sulfate13$79,187
DescovyEmtricitabine/Tenofov Alafenam28$64,293
JulucaDolutegravir/Rilpivirine16$56,823
ErtapenemErtapenem Sodium58$37,359
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam93$31,057
Etravirine19$22,916
Isentress HdRaltegravir Potassium12$22,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,234$959,788254 claims
Viiv Healthcare CompanyTivicay, Juluca$1,947$205,70963 claims
MerckIsentress, Isentress Hd$1,124$115,73358 claims
Johnson & JohnsonPrezcobix$344$80,91734 claims
Astellas Pharma US IncCresemba$903$79,18713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →